Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibSae‐Won Han, Noe Kyeong Kim|Journal of Clinical Oncology|2005Cited by 775
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumorsYonina R. Murciano‐Goroff, Joshua K. Sabari, Yasutoshi Kuboki et al.|Cancer Research|2023Cited by 37